Drug to avoid hip fraction

September 3, 2015 News BioVox

UCB announced that it obtained positive results in its clinical trial with its new drug, RomosozUmab, against osteoporosis. Romosozumab is designed to work by inhibiting the protein sclerostin, thereby increasing bone formation and decreasing bone breakdown.

A Phase III clinical trial to evaluate the safety, tolerability and efficacy of RomosozUmab was performed with 436 women suffering from osteoporosis with high risk for fracture. The effect of RomosozUmab was compared to the current treatment for osteoporosis, i.e. Teriparatide, on the hip bone mineral density. A statistically significant difference was found in favor of RomosozUmab.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter